IMMX — Immix Biopharma, Inc. stock price, charts and financials

QT92Immix Biopharma, Inc.

Immix Biopharma, Inc. (NASDAQ: IMMX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
12.50
-0.22-1.73%
OverviewShort InterestFilings
IMMXQT92Immix Biopharma, Inc.·NASDAQ
12.50-1.73%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
NKTR-1.84%$67.10RAPP-3.58%$40.45GHRS-1.60%$28.26ZYME-3.31%$26.57MESO+1.75%$15.13AGIO-1.61%$33.07ZBIO-1.47%$31.50RXRX+8.19%$3.83
Snapshot
Index-P/E-EPS (ttm)-Insider Own17.28%Shs Outstand54.40MPerf Week2.97%
Market Cap680.02MForward P/E-EPS next Y-0.86Insider Trans0.00%Shs Float43.40MPerf Month-5.23%
Enterprise Value449.02MPEG-EPS next Q-0.18Inst Own-Short Float22.16%Perf Quarter43.35%
Income-29.00MP/S0.00EPS this Y-Inst Trans-Short Ratio5.26Perf Half Y29.13%
Sales0.00P/B2.97EPS next Y-18.92%ROA-16.69%Short Interest9.62MPerf YTD139.01%
Book/sh4.21P/C2.93EPS next 5Y-ROE-38.44%52W High15.10 -17.22%Perf Year537.76%
Cash/sh4.26P/FCF-EPS past 3/5Y-ROIC-18.19%52W Low1.98 531.31%Perf 3Y352.90%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility5.44% 5.90%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-14.47%Oper. Margin0.00%ATR (14)0.80Perf 10Y-
Dividend Ex-Date-Quick Ratio25.13Sales Y/Y TTM-Profit Margin0.00%RSI (14)50.71Recom2.00
Dividend Gr. 3/5Y-Current Ratio25.13EPS Q/Q18.18%SMA20-5.91%Beta1.64Target Price23.33
Payout0.00%Debt/Eq0.01Sales Q/Q-SMA5010.12%Rel Volume2.38Prev Close12.72
Employees21LT Debt/Eq0.01EarningsNov 06SMA20040.77%Avg Volume1.76MPrice12.50
IPO DateDec 16, 2021Option/ShortYes / YesEPS/Sales Surpr.-5.00% -Net Debt/EBITDA5.57Volume4,183,905Change-1.73%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-15-26ReiteratedMizuhoOutperform$14 → $26
Aug-11-26ReiteratedMorgan StanleyOverweight$19
Aug-10-26ReiteratedHC Wainwright & Co.Buy$20 → $25
May-22-26ReiteratedHC Wainwright & Co.Buy$15 → $20
Mar-27-26ReiteratedHC Wainwright & Co.Buy$12 → $15
Feb-09-26InitiatedMizuhoOutperform$14
Dec-09-25ReiteratedHC Wainwright & Co.Buy$7.00 → $12
Jul-01-24InitiatedH.CBuy$7.00
Latest News· Times ET
Sep-15-26
Sep-15-2605:41AM
Mizuho Maintains Outperform on Immix Biopharma, Raises Price Target to $26Benzinga
Aug-24-26
Aug-24-2611:47PM
Immix Biopharma (NASDAQ:IMMX) Reaches New 12-Month High – Still a Buy?defenseworld.net
Aug-13-26
Aug-13-2606:00AM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMXprnewswire.com
Aug-11-26
Aug-11-2602:23PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMXglobenewswire.com
07:56AM
Morgan Stanley Maintains Overweight on Immix Biopharma, Lowers Price Target to $19Benzinga
Aug-10-26
Aug-10-2604:10AM
HC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $25Benzinga
Aug-06-26
Aug-06-2603:57PM
IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Lawbusinesswire.com
Aug-04-26
Aug-04-2612:49PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMXglobenewswire.com
05:15AM
Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conferenceglobenewswire.com
Jul-30-26
Jul-30-2606:00AM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMXprnewswire.com
Jul-23-26
Jul-23-2604:15AM
IMMX INVESTIGATION: Securities Fraud Investigation by Block & Leviton Could Allow Immix Biopharma Investors to Recover Lossesnewsfilecorp.com
Jul-22-26
Jul-22-2603:17AM
Needham Initiates Coverage On Immix Biopharma with Buy Rating, Announces Price Target of $21Benzinga
Jul-21-26
Jul-21-2609:51AM
Immix Biopharma Investigated by the Portnoy Law Firmglobenewswire.com
Jul-20-26
Jul-20-2601:33PM
IMMX INVESTOR ALERT: Holzer & Holzer, LLC Announces Investigation of Immix Biopharma, Inc.globenewswire.com
08:13AM
Immix Biopharma Stock Drops Significantly On News of Chief Medical Officer Arrest - IMMX Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Potential Securities Fraud Claimsnewsfilecorp.com
Company

Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue
000————
Cost of Goods Sold Incl. D&A
000————
Gross Profit
000————
Selling, General and Administrative Excl. Other14117————
Research and Development16119————
Other Operating Expense010————
Operating Income-30-23-16————
Interest Expense
000————
Unusual Expense
———————
Non-Operating Income (Expense)111————
Net Income Before Taxes-29-22-16————
Income Taxes
000————
Consolidated Net Income-29-22-15————
Net Income From Continuing Operations-29-22-16————
Net Income-29-22-15————
EPS (Recurring)-0.89-0.76-0.89————
EPS (Basic, Before Extraordinaries)-0.89-0.76-0.89————
EPS (Diluted)-0.89-0.76-0.89————
EBITDA-30-22-16————
Other After Tax Adjustments
———————
Stock Option Compensation Expense
———————
Price To Earnings Ratio
———————
Price To Sales Ratio
———————
Gross Margin
———————
Operating Margin
———————
Net Margin
———————
Shares Outstanding332817————
Market Capitalization17362118————
Operating Lease Expense
———————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$16.35$12.28$8.21$4.15$0.08● Close Price0.00K2.54K5.09K7.63K10.17KUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Rachman Ilya MCEO and ChairmanDec 10 '25Buy6.677464,9761,141,683Dec 10
Morris Gabriel SCFODec 10 '25Buy6.587705,067291,429Dec 10
Morris Gabriel SCFODec 08 '25Option Exercise0.80216,000172,800426,844Dec 10
Rachman Ilya MCEO and ChairmanSep 17 '25Buy2.022,5005,0501,140,937Sep 17
Morris Gabriel SCFOSep 16 '25Buy1.972,6005,122290,659Sep 17
Rachman Ilya MCEO and ChairmanJun 18 '25Buy2.292,1784,9991,138,437Jun 20
Morris Gabriel SCFOJun 18 '25Buy2.282,2255,071288,059Jun 20
Hsu JasonDirectorDec 23 '24Buy2.1940,00087,680893,000Dec 26
Hsu JasonDirectorDec 20 '24Buy2.177,70016,678853,000Dec 26
Hsu JasonDirectorAug 22 '24Buy2.258,10018,233845,300Aug 26
Hsu JasonDirectorAug 21 '24Buy2.2315,00033,390837,200Aug 26
Ng CareyDirectorAug 16 '24Buy1.8610,00018,60020,000Aug 19
Hsu JasonDirectorJul 24 '24Buy2.156,00012,877822,200Jul 31
Hsu JasonDirectorJul 18 '24Buy2.073,2006,639816,200Jul 31
Rachman Ilya MCEO and ChairmanJun 07 '24Buy2.132,6005,5381,136,259Jun 10
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.